Skip to main content
. 2022 Apr 21;8(7):1053–1058. doi: 10.1001/jamaoncol.2022.0752

Figure 1. Anti–SARS-CoV-2 Spike Protein Receptor Binding Domain (Anti-RBD) and Neutralizing Antibody Response to Vaccines.

Figure 1.

A, Anti-RBD titers for all 453 patients. A total of 1042 blood samples were obtained for antibody testing (112 at T0, 176 at T1, 293 at T2, 336 at T3, 98 at T4, and 27 after the third dose). Each dot represents a patient sample. The x-axis indicates time points for the collection of samples: baseline before vaccination (T0), 14 days after the first dose and before the second dose of a messenger RNA (mRNA) vaccine (T1), 1 month (±1 week) after the second dose of an mRNA vaccine or 2 months after the JNJ-7846735 vaccine (T2), 3 months (±4 weeks) after the second dose of an mRNA vaccine or 4 months after the JNJ-7846735 vaccine (T3), 6 months (±4 weeks) after the second dose of an mRNA vaccine or 7 months after the JNJ-7846735 vaccine (T4), and 4 weeks after the booster (third dose of an mRNA vaccine [T61]). The lower horizontal dotted line indicates seropositivity (0.8 U/mL), and the upper horizontal dotted line indicates the threshold value of 100 U/mL. The error bars indicate geometric mean titers (GMTs) with 95% CIs (whiskers). The GMTs are also displayed numerically. There was a 20-fold increase in titers 1 month after a booster compared with T2 (1 month after completion of the primary vaccination). Only 3 patients had titers lower than 100 U/mL after the booster, and all of them had a hematologic malignant tumor. B, Box-and-whisker plots of the percentage of neutralization using the Surrogate Viral Neutralization Test. The whiskers indicate the range, the boxes indicate the IQR, and the horizontal line within each box indicates the median. The dots indicate the outliers. The horizontal dotted line indicates threshold of neutralization (30%). The median percentage of neutralization was 1% at T0, 18% at T2, 81% at T2, and 71% at T3.